November 14th 2024
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Dr. Langer Discusses Current Treatment Strategies for Patients With Non-Driver Nonsquamous NSCLC
September 13th 2017Corey J. Langer, MD, Perelman Center for Advanced Medicine, Hospital of the University of Pennsylvania, discusses current treatment strategies for patients with non-driver nonsquamous non-small cell lung cancer (NSCLC).
Watch
Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC
September 13th 2017Corey J. Langer, MD, Perelman Center for Advanced Medicine; Hospital of the University of Pennsylvania, discusses ongoing clinical trials for patients with non-driver non-small cell lung cancer (NSCLC).
Watch
Dr. Langer Discusses Remaining Challenges With the Non-Driver NSCLC Population
September 13th 2017Corey J. Langer, MD, Perelman Center for Advanced Medicine; Hospital of the University of Pennsylvania, discusses remaining challenges in the treatment of patients with non-driver non-small cell lung cancer.
Watch
Enhanced Surveillance Post-Surgery Not Associated With Longer Survival in NSCLC
September 12th 2017There was no overall survival improvement seen by expanding surveillance from chest x-ray to follow-up with PET-CT scan after surgery for patients with early-stage non–small cell lung cancer, according to data reported during the 2017 ESMO Congress.
Read More
Nab-Paclitaxel Demonstrates Efficacy Alone and With Durvalumab in NSCLC
September 12th 2017According to findings presented at the 2017 ESMO Congress, nab-paclitaxel monotherapy demonstrated efficacy in patients with pretreated advanced nonsquamous non–small cell lung cancer that is not improved by the addition of CC-486.
Read More
Continuous Nivolumab Treatment Leads to Improved PFS in Pretreated NSCLC
September 12th 2017In patients with previously treated advanced non-small cell lung cancer, <sup> </sup>superior progression-free survival was induced with continuous treatment with nivolumab until disease progression compared with a 1-year fixed duration treatment.
Read More
Significance of the Phase III FLAURA Study in EGFR+ NSCLC
September 11th 2017Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the randomized phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non-small cell lung cancer.
Watch
PFS Benefit in NSCLC Immunotherapy Predicted With Liquid Biopsy for Mutation Burden
September 10th 2017According to a retrospective analysis of a randomized study presented at the 2017 ESMO Congress, a liquid biopsy that measures tumor mutational burden showed promise for predicting benefit in patients with non–small cell lung cancer treated with a checkpoint inhibitor.
Read More
Durvalumab a Promising Option for Patients With Locally Advanced Lung Cancer
September 9th 2017Treatment with the PD-L1 inhibitor durvalumab (Imfinzi) improved median PFS by 11.2 months compared with placebo for patients with locally advanced, unresectable stage III non–small cell lung cancer who had not progressed following chemoradiotherapy, according to phase III results from the PACIFIC trial presented at the 2017 ESMO Congress.
Read More
Results of Phase III FLAURA Study Show Benefit of Frontline Osimertinib in EGFR+ NSCLC
September 9th 2017In results from the phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with <em>EGFR</em>-mutant non–small cell lung cancer, osimertinib demonstrated a progression-free survival rate of 18.9 months (95% CI, 12.5-21.4), which was significantly improved over standard therapy.
Read More
Alectinib Demonstrates Promising Efficacy for ALK+ NSCLC With CNS Brain Metastases
September 9th 2017According to findings from the phase III ALUR and ALEX studies announced ahead of the 2017 ESMO Congress,<sup> </sup>Alectinib demonstrated promising efficacy for patients with <em>ALK</em>-translocated non–small cell lung cancer with central nervous system metastases in both the first- and second-line setting.
Read More
Late-Breaking Abstracts at ESMO Could Potentially Change Lung Cancer Practice
September 7th 2017The 2017 ESMO Annual Congress, taking place September 8 to 12 in Madrid, Spain, will feature several late-breaking abstracts that are poised to change the future of treatment for patients with lung cancer, pending their results, including the phase III PACIFIC and FLAURA studies.
Read More
Epacadostat/Pembrolizumab a Promising, Timely Combo for Melanoma, Expert Says
September 7th 2017Omid Hamid, MD, shares the top melanoma abstracts to look out for at the 2017 ESMO Annual Congress, which is taking place September 8 to 12 in Madrid, Spain, as well as some background on the promising phase I/II results he will be presenting for the combination of epacadostat plus pembrolizumab in patients with advanced melanoma.
Read More
Nonbiomarker, Nonsquamous NSCLC: Diagnosis, Statistics, Staging, and Testing
September 5th 2017Non-small cell lung cancer is the most common type of lung cancer, accounting for approximately 80% to 85% of lung cancer cases, whereas small cell lung cancer comprises approximately 10% to 15% of lung cancer cases.
Read More
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLC
September 5th 2017Systemic anticancer therapy recommendations for patients with stage IV non–small cell lung cancer (NSCLC) depend on individual tumor histology, patient performance status, and driver oncogene biomarker status, which are most often anaplastic lymphoma kinase (ALK) translocation or epidermal growth factor receptor (EGFR) mutation.
Read More
Dr. Bazhenova on Current Treatment Strategies for Patients With Nonsquamous NSCLC
September 1st 2017Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the currently available treatment strategies for patients with non-driver non–small cell lung cancer.
Watch
Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab
September 1st 2017Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the factors to take into consideration when treating a patient with non-driver non–small cell lung cancer with bevacizumab (Avastin).
Watch
Dr. Bazhenova on Potential Impact of Immunotherapy in Non-Driver NSCLC
September 1st 2017Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses what potential impact immunotherapy agents could have on outcomes for patients with non-driver non–small cell lung cancer.
Watch
Dr. Bazhenova on Remaining Challenges and Future Treatment Landscape of Non-Driver NSCLC
September 1st 2017Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses ongoing and remaining challenges in the field of non-driver non–small cell lung cancer, as well as a look toward the future treatment landscape.
Watch
Therapeutic Options Developing for Nondriver NSCLC, But Challenges Remain
September 1st 2017Corey Langer, MD, provides details on the goals and implications of the KEYNOTE-021 trial. Moreover, he discusses the current arena in NSCLC treatment and the obstacles that remain in treating patients without driver mutations effectively.
Read More